Do these 3 things before closing this tab:
1Clear out junk files and repair common Windows errors2Scan for outdated or missing drivers - takes under a minute3Repair Windows errors before they cause bigger problemsThe FDA plans to highlight aging and longevity medicine in its next Focus Areas of Regulatory Science (FARS) report, according to remarks by FDA Chief Scientist Steven Kozlowski at the 13th Aging Research & Drug Discovery Meeting in Boston. GEN reported on October 2, 2026, that Kozlowski expected the update early in federal fiscal year 2027; he gave no exact release date. The announcement signals interest in research tools for measuring aging and assessing interventions, not approval of an anti-aging treatment or a new regulatory pathway.
What the FDA’s planned FARS update means
FARS is a report on areas where the FDA sees a need for continued, targeted investment in regulatory science. The agency defines regulatory science as developing tools, standards, and approaches to assess the safety, efficacy, quality, and performance of products it regulates. The first FARS report appeared in 2021, and the first update followed in 2022, according to the FDA’s December 6, 2022 presentation.
A FARS priority identifies scientific work the agency considers important; it is not a clinical guideline, approval decision, or promise that a particular therapy will be developed. GEN reported that aging research and longevity medicine were absent from the 2022 report, providing context for why their planned inclusion would represent a new emphasis.
What FDA officials said they want to solve
Kozlowski described aging as a shared risk factor for many chronic diseases and asked how it could be quantified through both biological measures and clinical outcomes. His remarks point to a measurement challenge: researchers need ways to assess aging-related changes that are scientifically useful and can support feasible, comparable clinical trials.
Free tools Windows power users keep installed
One-click scans. No signup required.
#1 Best Overall
He also described the potential value of a broadly shared, precompetitive endpoint that could bridge research programs, be used widely, support feasible trial designs, and serve as a standard for later work. Those were attributes of a useful endpoint in his conference comments—not an FDA decision that any endpoint has been qualified or accepted.
Acting Chief of Staff Lowell M. Zeta called longevity and healthspan important topics for FDA and HHS. GEN described healthspan as the years lived free from long-term disease or disability. Zeta said, “To the extent that we can be and should be evolving our programs to help you all solve the challenges, that’s what we want to hear.”
Rank #2
Possible ways to study aging-related effects
FDA Office of Drug Evaluation Sciences director Jeffrey Siegel described two possible approaches during the panel. He did not present either as an adopted FDA pathway.
Look across multiple age-related diseases
One possible approach would examine whether a treatment’s mechanism affects several chronic diseases associated with aging. This would require evidence across those conditions; the panel discussion did not specify a qualifying mechanism, disease set, or evidentiary standard.
PC Slower Than It Used to Be?
A free scan shows the junk files, broken settings and background clutter dragging Windows down - then fixes them in one click.Free scan · Windows 10 & 11Crashes, No Sound, or Screen Glitches?
Random freezes, missing sound and display glitches usually trace back to one bad driver. Find and replace yours safely.Free scan · under a minuteRank #3
Measure broader functional domains
Another possibility would be to assess functions affected by aging, including cognition, frailty, hearing, or vision. The remarks did not identify a specific measure or establish that any of these domains can serve as an accepted endpoint for an aging-related therapy.
Biological measures, clinical outcomes, and digital data
The conference comments raised both biological and clinical measurement, but named no validated aging biomarker or clinical endpoint. Establishing a measure that is reliable and useful in trials is different from showing that a product improves it in a way that supports a regulatory claim.
The FDA’s Digital Health Technologies for Drug Development program describes how digital tools can collect data remotely and support continuous or novel clinical measures, including work on digitally derived endpoints. That general program information does not mean the FDA has selected a wearable, sensor, or digital measure for the aging-related FARS update.
What the announcement does not establish
- It does not classify aging as a disease or establish a general FDA-approved “anti-aging” indication.
- It does not announce an approved longevity drug, a named therapy, or a validated aging measure.
- It does not qualify or accept a shared endpoint; the endpoint discussion was about what could be useful in future research.
- It does not set out the next report’s full outline, specific research questions, funding commitments, or deliverables.
When is the next FARS report expected?
GEN reported Kozlowski’s expectation that it would appear early in federal fiscal year 2027. No specific publication date was given. The timing and planned emphasis should therefore be understood as reported plans, not a published FDA commitment with detailed deliverables.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
